Osage University Partners, a Philadelphia-area venture firm that only invests in tech transfer spinouts, just closed its second fund – valued at $215 million.
About half of that funding will likely go towards life sciences companies – particularly in the therapeutics space, said managing partner William Harrington. Cancer, GI and cardiovascular drugs are the most interesting to Osage, he said, though the firm’s interested in diversifying its holdings. Most of the other investment will be made in tech companies.